Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817121 | 1.00 | ESR2 (0.53) | ESR2SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL22817118 | 1.00 | ESR2 (0.53) | ESR2SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL9870878 | 0.89 | SLC6A2 (0.58) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL7153005 | 0.85 | ESR2 (0.55) | ESR2SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL7153002 | 0.85 | ESR2 (0.55) | ESR2SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL2407 | 0.81 | SLC6A2 (0.65) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL15335800 | 0.81 | SLC6A2 (0.70) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL22817205 | 0.80 | ESR2 (0.53) | ESR2SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL4470188 | 0.80 | ESR2 (0.52) | ESR2SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL4331978 | 0.79 | SLC6A2 (0.68) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | ESR2 4547/4885SLC6A4 1967/4885SLC6A3 1268/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ESR2 4547/4885SLC6A4 1967/4885SLC6A3 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.